. "N-[-1--2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide"@en . . . . . . "38398984"^^ . "18"^^ . "2"^^ . . . . . "1445752"^^ . "26"^^ . . . . . . . . . . "4"^^ . . . "CCCCCn1c2ccccc2cCN[C@@H]CN"@en . . . "Anlage II"@en . . . . . . . . . . . . . . . . "AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication. AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for \u03949-THC in rat discrimination studies, while being 1.5x more potent. There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid."@en . "Schedule I"@en . . . . . . . . . "7224"^^ . . "71301472" . . "Schedule II"@en . "Class B"@en . "1"^^ . . "6J3KC3S2PA" . . . "6"^^ . "AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication. AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for \u03949-THC in rat discrimination studies, while being 1.5x more potent. There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid."@en . . . . . . . . . . . . . . . "1445752-09-9" . . . . . . . . "28537615"^^ . "GIMHPAQOAAZSHS-HNNXBMFYSA-N"@en . "1082421208"^^ . "71301472"^^ . . "AB-PINACA"@en .

  NODES